Objectives: To compare the effects of the b-blocker atenolol with the angiotensin receptor blocker ðARBÞ losartan on plasma tissue-type plasminogen activator ðtPAÞ activity and mass concentration, plasminogen activator inhibitor-1 ðPAI-1Þ activity, tPA/PAI-1 complex, and von Willebrand factor ðVWFÞ. Design: A prespecified, explorative substudy in 22 patients with hypertension and left ventricular hypertrophy ðLVHÞ performed within randomized multicenter, double-blind prospective study. Results: After a median of 36 weeks of treatment, there were significant differences between the treatment groups, atenolol versus losartan, in plasma median levels of tPA mass ð11.9 vs 7.3 ng/mL, P ¼ .019Þ, PAI-1 activity ð20.7 vs 4.8 IU/mL, P ¼ .030Þ, and tPA/PAI-1 complex ð7.1 vs 2.5 ng/mL, P ¼ .015Þ. In patients treated with atenolol, median levels of tPA mass ð8.9-11.9 ng/mL, P ¼ .021Þ and VWF ð113.5%-134.3%, P ¼ .021Þ increased significantly, indicating a change toward a more prothrombotic state. No significant changes occurred in the losartan group. Conclusion: Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group. These findings suggest different fibrinolytic and hemostatic responses to treatment in hypertensive patients with LVH.
Introduction
There is growing evidence suggesting that activation of the renin-angiotensin-aldosterone system ðRAASÞ, a main pathway of hypertension pathophysiology, interacts with the fibrinolytic system. 1, 2 Activation of the RAAS is also associated with an increased risk of cardiovascular events independent of blood pressure elevation. 3 We have shown earlier that the angiotensin-converting enzyme ðACEÞ inhibitor enalapril in postmyocardial infarction patients seemed to have a favorable effect on the fibrinolytic system. 4 Angiotensin-converting enzyme inhibitor treatment can improve fibrinolysis in 2 theoretical ways: via endothelial derived increased bradykinin-induced tissue-type plasminogen activator ðtPAÞ release and/or by inhibition of angiotensin II. 5 An increase of tPA activity and decrease of plasminogen activator inhibitor ðPAI-1Þ activity by an ACE inhibitor are thus favorable for improving fibrinolysis.
von Willebrand factor ðVWFÞ is also synthesized by the vascular endothelium besides from megakaryocytes. 6 Although VWF and fibrinolytic variables are differently regulated, 7 a high concentration of VWF has also been associated with increased risk of reinfarction and the all-cause mortality in survivors of myocardial infarction. 8 For this reason and because components of the fibrinolytic system and VWF are endothelial derived, the current study brings new information on the effects of common antihypertensive drugs both on the fibrinolytic system and on VWF in hypertensive patients with left ventricular hypertrophy ðLVHÞ. Because angiotensin receptor inhibitors ðARBsÞ only inhibit the effects of angiotensin II and not the bradykinin-induced responses, the consequences of ARB treatment on the fibrinolytic system might differ from those of ACE inhibitors. An ARB may have an advantage over an ACE inhibitor by its direct receptor blockade, thereby avoiding the escape mechanism described for ACE inhibitors but there are diverging and contradictory results of the effects of ARBs on the fibrinolytic system and VWF. Our null hypothesis was that losartan would have no better effect on fibrinolysis than the b-blocker atenolol, which we considered an appropriate referent drug due to its neutral effect on fibrinolysis. 9 The aim of the current mechanistic study was to explore the effects of the ARB losartan compared to the b-blocker atenolol on tPA activity and mass concentration, tPA/PAI-1 complex, PAI-1 activity, and VWF.
Methods
This was a prespecified, investigator-initiated explorative substudy of the REGression of LVH with the AII Antagonist Losartan ðREGAALÞ study, which was a multicenter, multinational, randomized, double-blind, parallel-group study in patients with hypertension and LVH. 10 Patients included in the REGAAL study had mild-to-moderate hypertension and LVH ðleft ventricular mass index for males ! 130 g/m 2 , and females ! 110 g/m 2 and a left ventricular diastolic diameter of < 60 mmÞ, verified by echocardiography. Inclusion and exclusion criteria for the substudy were the same as for the REGAAL study and has been described in detail earlier. 10 Patients were randomized into 2 groups that received atenolol 50 mg once daily or losartan 50 mg once daily. Patients were instructed to take the study medication at the same time each day, preferably between 08:00 and 10:00 AM. Patient visits were scheduled at 6, 12, 24, and 36 weeks. Those who did not reach goal blood pressure ð<140/90 mmHgÞ after 6 weeks of treatment also received hydrochlorothiazide ðHCTZÞ 12.5 mg daily. If goal blood pressure still was not met within 12 weeks of treatment, the patients received 100 mg of study drug and 25 mg of HCTZ daily.
In the REGAAL main study, 10 110 patients ð66 males, 44 females; aged 57 + 11 yearsÞ were randomized to atenolol and 115 patients ð77 men and 38 women; aged 57 + 11 yearsÞ were randomized to losartan. Heart rate was 72 + 10 versus 70 + 10 beats/min, sitting systolic blood pressure ðSiSBPÞ was 169 + 15 versus 169 + 15 mm Hg, sitting diastolic blood pressure ðSiDBPÞ was 99 + 8 versus 98 + 9 mm Hg, and left ventricular mass was 148 + 30 versus 150 + 30 g/m 2 in the atenolol and losartan groups, respectively.
Of 111 patients separately screened in Sweden, New Zealand, and Canada, we recruited 22 who fulfilled inclusion and had no exclusion criteria. Of the 22 patients enrolled in this substudy, 2 had incomplete sample sets at baseline but was followed and analyzed at the end of the study. During the study, 2 patients stopped treatment ð1 in each groupÞ due to adverse events ðsinus arrest, asthenia/fatigueÞ after 2 and 4 weeks, respectively.
Venous blood samples were drawn at baseline and the others after approximately 36 weeks except for 2 above withdrawn patients who had their last sampling at 2 and 4 weeks. Blood was stored in prechilled, 5-mL Stabilyte tubes containing 0.5 mL strong acidic citrate ðpH 4.3Þ purchased from Biopool AB ðUmeå, SwedenÞ. To avoid confounding by the known diurnal variation, blood was drawn after an overnight fast at 08:00 to 10:00 AM, after patients rested by sitting in a chair for at least 10 minutes. The sample tubes were immediately centrifuged at 2000g for 15 minutes at 4 C. The plasma was dispensed into 3 aliquots and kept frozen at À80 C for 1 to 2 years until analysis.
Analysis was done on Stabilyte plasma using enzyme-linked immunosorbent assay ðELISAÞ. 11 Reference values were according to those given by the manufacturers. The tPA activity ðChromolize tPAÞ, PAI-1 activity ðChromolize PAI-1Þ, tPA mass ðImulyse tPAÞ, and tPA/PAI-1 complex ðTintElize tPA/PAI-1 complexÞ concentrations were measured with reagent kits purchased from Biopool AB. In our hands, the interassay coefficient of variation ðCVÞ was 9.5% for tPA activity, 5.4% for PAI-1-activity, 11.4% for tPA mass, and 4.1% for tPA/PAI-1 complex. Enzymelinked immunosorbent assay reagents for VWF 12 were purchased from DAKO ðCopenhagen, DenmarkÞ. In our hands, CV for VWF was 5.2%. All samples were thawed in a 37 C water bath and analyzed directly afterward by staff blinded to study drug treatment and sample time point.
Statistical Analysis
Baseline characteristics were expressed as mean + 1 SD. Fibrinolytic and VWF data were expressed as median values because they did not display normal distribution. A nonparametric analysis using an analysis of covariance ðANCOVAÞ model on the rank transformation was performed with the model adjusted for baseline systolic blood pressure. We used the Wilcoxon signed-rank test to analyze differences in each treatment group from baseline to end of treatment. This substudy was prespecified and designed to demonstrate a statistically significant ðP .05Þ and clinically significant reduction of tPA mass ðfrom 15.0 to 12.0 mg/L, SD ¼ 4Þ and VWF ðfrom 200% to 140%, SD ¼ 80Þ. For this purpose, a minimum of 29 patients per group were calculated to be necessary to yield a power of 80% ðunpaired 2-tailed t testÞ, but we failed for administrative reasons to reach this prespecified number. Based on the achieved results in the current study, a new power calculation with the same power and significance level as above was performed. We found the following sample sizes to be needed for each studied variables: tPA activity ¼ 11, PAI-1 activity ¼ 14, tPA/ PAI-1 complex ¼ 6, tPA mass concentration ¼ 31, and VWF ¼ 33. All statistical analyses were performed with SPSS software version 11.5.
The research protocol was approved by the locally appointed ethics committees and the study complied with the Declaration of Helsinki. Written informed consent was collected from all participants at inclusion in the study.
Results
We included 22 patients, 11 in the losartan group and 11 in the atenolol group, in the current substudy of REGAAL. The baseline characteristics of participants are shown in Table 1 . Patients in this substudy differed from those not included in the substudy, in that they had significantly higher baseline systolic blood pressure. The baseline characteristics between the 2 treatment groups in the current substudy differed significantly only for systolic blood pressure, which was significantly higher in the atenolol group ð180.8 mm HgÞ compared with the losartan group ð160.0 mm Hg; P < .001Þ.
After a median of 36 weeks of treatment, there were significant reductions in systolic blood pressure in the losartan ðÀ20.0 mm Hg, À12.5%, to 140.0 mm Hg; P < .001Þ and atenolol ðÀ23.3 mm Hg, À12.7%, to 157.5 mm Hg; P ¼ .001Þ groups and in diastolic blood pressure in the losartan ðÀ11.7 mm Hg, À11.8%, to 87.8 mm Hg; P < .001Þ and atenolol ðÀ9.2 mm Hg, À9.6%, to 87.1 mm Hg, P ¼ .023Þ groups. After a median of 36 weeks of treatment, left ventricular mass decreased significantly in the losartan group ðÀ30.2 to 259.9 g; P ¼ .002Þ but not in the atenolol group ðÀ22.5 to 269.5 g; P > .05Þ. There were no significant between-group differences at baseline for the fibrinolytic variables ðTable 2, Figure 1 , panels A-E.Þ. After 36 weeks, tPA mass ð2.0 ng/mL, 34.0% increase to 11.9 ng/mL; P ¼ .021, Figure 1 , panel DÞ and VWF ð20.8%, 18.4% increase to 134.3%; P ¼ .021, Figure 1 , panel EÞ increased significantly in the atenolol group, while there were no significant changes in any component of the fibrinolytic system or VWF from baseline to end of treatment in the losartan group ðFigure 1, panels A-EÞ. At the end of treatment, there were significantly lower fibrinolytic variables in the losartan group compared with the atenolol group ðPAI-1 activity: losartan 4.8 IU/mL vs atenolol 20.7 IU/mL, P ¼ .031; tPA/ PAI-1 complex: losartan 2.5 ng/mL vs atenolol 7.1 ng/mL, P ¼ .017; and tPA mass: losartan 7.3 ng/ mL vs atenolol 11.9 ng/mL, P ¼ .027Þ adjusted for differences in baseline systolic blood pressure. These differences remained significant ðPAI-1, P ¼ .030; tPA/PAI-1 complex, P ¼ .015; and tPA mass, P ¼ .019Þ after adjustment for change in left ventricular mass, due to the known interaction between LVH and endothelial dysfunction ðTable 2Þ. 13 
Discussion
The main finding of the current study was that after a median of 36 weeks of treatment, patients with hypertension and LVH randomized to losartan therapy had significantly lower values of PAI-1 activity, tPA/PAI-1 complex, and tPA mass concentration than those randomized to atenolol. These findings suggest that patients treated with losartan achieved an unchanged fibrinolytic balance than those treated with atenolol. In fact, patients in the atenolol group had significantly increased levels of tPA mass concentration and VWF. The findings in the losartan group were consistent toward lower values for PAI-1 activity, tPA/PAI-1 complex, and tPA mass concentration and with preserved tPA activity. The overall trend was thus a preserved fibrinolytic balance in the losartan group as compared with a more prothrombotic fibrinolytic and hemostatic state in the atenolol group.
Our findings are consistent with and extend a previous study in 115 Greek untreated patients with hypertension where the ARB irbesartan significantly decreased PAI-1 antigen level. 14 In our study, there were significant differences also for PAI-1 activity and tPA mass concentration and the tPA/PAI-1 complex, which strengthens the evidence for beneficial effects on the fibrinolytic system during treatment with an ARB as compared with a b-blocker. Patients in the study by Makris et al 14 were previously untreated and differed from our hypertensive patients who had signs of organ damage with LVH. It is likely that hypertensive patients with established LVH may have more advanced endothelial dysfunction than patients with untreated hypertension, as those in the study by Makris et al, 14 making it easier to show beneficial effects on fibrinolytic disturbances from ARB treatment. However, Sakata et al 15 found significantly increased levels of PAI-1 and PAI-activity after 6 months of treatment with losartan, whereas there was no change in the group treated with the ACE inhibitor quinapril. The main differences compared with our study were that Sakata et al 15 treated patients with uncomplicated hypertension and that comparison was with an ACE inhibitor. Hypertension is considered the most powerful risk factor in predicting stroke events, 16 especially if it is complicated by LVH. There is also a known and important interaction between LVH and endothelial dysfunction. The combination of these consequences of hypertension almost doubles the risk of cardiovascular events. 13 The Losartan Intervention For Endpoint reduction in hypertension ðLIFEÞ study showed that older patients with hypertension and LVH randomized to losartan-based compared with atenolol-based antihypertensive treatment had decreased stroke incidence even though blood pressure was decreased similarly in both treatment groups. 17 Because the patients in the LIFE study and in the current study had similar clinical characteristics ðie, hypertension with LVHÞ, our findings might indicate a mechanism related to hemostasis and fibrinolysis as a possible explanation of the difference in stroke events in the LIFE study. 10, 17 The differences in fibrinolytic and hemostatic balance observed in the current study for those treated with losartan compared with atenolol might be of importance for cardiovascular outcome. Previous studies have also shown that high levels of tPA mass and VWF are associated with an increased risk of developing cardiovascular events. 18 In patients with coronary heart disease, it has been shown that endothelial fibrinolytic capacity, as measured by stimulated t-PA release, predicts the future risk of cardiovascular death, myocardial infarction, ischemic stroke, and emergency hospitalization for unstable angina. 19 Although b-blockers have an effect on the blood vessels and a plausible secondary effect on the fibrinolytic system, atenolol has no direct effect on the fibrinolytic system. 9 We found that tPA mass and VWF significantly increased over time in the atenolol-treated group, suggesting that deterioration in the fibrinolytic balance was not counteracted by atenolol as it seemed to be for losartan. This might suggest different fibrinolytic and hemostatic responses to treatment in hypertensive patients with LVH.
There are a number of limitations to our study. The limited number of patients in the current study implies that conclusions from this study should be drawn with great caution. However, despite this low sample size, and a rather short study period of 36 weeks, significant differences in the measurements of interest were observed between groups, as well as within the atenolol group, warranting further studies of the effects of b-blockers and inhibitors of the RAAS on the fibrinolytic and hemostatic systems. The between-group systolic blood pressures were significantly different at baseline and while systolic blood pressure decreased to a controlled level at the end of treatment in the losartan group ðfrom 160.0 to 140.0 mm Hg, À12.5%Þ, systolic blood pressure decreased significantly, but remained uncontrolled, in the atenolol group ðfrom 180.8 to 157.5 mm Hg, À12.7%Þ. The percentage systolic reduction was almost equal in both treatment groups and other studies 10, 17 showed comparable blood pressure control after <36 weeks of losartan-based compared with atenolol-based treatment, 10,20 so the failure to control blood pressure in the atenolol group in the current study may have been by chance due to the small sample size. It is important to take differences in blood pressure into account as hypertension itself is linked to endothelial dysfunction. 13 However, adjustment for this difference of blood pressure and left ventricular mass index changed the P value only marginally, suggesting that the main effect on fibrinolysis and VWF was due to drug treatment. Gender differences were not analyzed due to the small sample size but should be an important goal in future studies. Despite all limitations, the current study adds new information of potential differences on the fibrinolytic system of 2 common antihypertensive drugs. However, larger studies with a longer follow-up period with b-blockers or ARBs are warranted to enable a deeper understanding of the mechanisms and effects of treatment on the fibrinolytic system and VWF with regard to onset and duration of effects, as well as the impact of confounding factors.
In conclusion, there was a preservation of the fibrinolytic balance in the losartan group as compared with a more prothrombotic fibrinolytic and hemostatic state in the atenolol group in patients with hypertension and LVH. These differences between atenolol and losartan, if verified in future studies, may be an important pathophysiological mechanism behind different cardiovascular outcomes in patients with hypertension and LVH.
